Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma

Published:2009-06-30 Issue:5 Volume:28 Page:670-676
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Wu Jennifer,Henderson Charles,Feun Lynn,Van Veldhuizen Peter,Gold Philip,Zheng Hui,Ryan Theresa,Blaszkowsky Lawrence S.,Chen HaoBin,Costa Max,Rosenzweig Barry,Nierodzik MaryLynn,Hochster Howard,Muggia Franco,Abbadessa Giovanni,Lewis Jonathan,Zhu Andrew X.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-009-9286-9.pdf

Reference32 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics. CA Cancer J Clin 58:71–96

2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823

3. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK (2003) J Natl Cancer Inst 95:1276–1299

4. Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Onc 27:1485–1491

5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliverira AD, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. NEJM 359:378–390

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural agents' role in cancer chemo-resistance prevention and treatment: molecular mechanisms and therapeutic prospects;PHARM PRACT-GRANADA;2024

2. Pharmacological profile and clinical study results of darinaparsin (DARVIAS<sup>®</sup> injection 135 ‍mg), an organic arsenic product, for relapsed or refractory peripheral t-cell lymphoma;Folia Pharmacologica Japonica;2023-09-01

3. AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer;Journal of Zhejiang University-SCIENCE B;2023-03

4. Darinaparsin: First Approval;Drugs;2022-11

5. Targeting Drug Chemo-Resistance in Cancer Using Natural Products;Biomedicines;2021-09-29